Reduktion i serum- CTX blev fastholdt i de 2 år, med over halvdelen af patienterne klassificeret som respondenter i begge behandlingsgrupper.
Serum CTX reduction was maintained over the 2 years, with more than half of the patients identified as responders in both treatment groups.